Advertisement

Hepatic Resection for Non-functional Neuroendocrine Liver Metastasis: Does the Presence of Unresected Primary Tumor or Extrahepatic Metastatic Disease Matter?

  • Jun-Xi Xiang
  • Xu-Feng Zhang
  • Eliza W. Beal
  • Matthew Weiss
  • Luca Aldrighetti
  • George A. Poultsides
  • Todd W. Bauer
  • Ryan C. Fields
  • Shishir Kumar Maithel
  • Hugo P. Marques
  • Timothy M. Pawlik
Gastrointestinal Oncology

Abstract

Objectives

The objective of this study was to assess the impact of unresected primary tumor, as well as extrahepatic metastasis, on the long-term prognosis of patients undergoing hepatic resection for non-functional neuroendocrine liver metastasis (NF-NELM).

Methods

Patients who underwent hepatic resection for NF-NELM were identified from a multi-institutional database. Data on clinical and pathological details, as well as the long-term overall survival (OS) were obtained and compared. Propensity score matching was performed to generate matched pairs of patients.

Results

Among the 332 patients with NF-NELM, 281 (84.6%) underwent primary tumor resection, while 51 (15.4%) did not. Patients who underwent primary resection were more likely to have a pancreatic primary and metachronous NELM. The long-term OS of patients who did and did not have the primary neuroendocrine tumor (NET) resected was comparable on both unmatched (10-year survival rate 66.8% vs. 54.0%, p = 0.192) and matched (10-year survival rate 75.7% vs. 60.4%, p = 0.271) analyses. In contrast, patients with NF-NELM and extrahepatic metastasis had a worse OS following resection compared with patients who had intrahepatic-only metastasis on unmatched (10-year survival rate 37.5% vs. 69.3%, p = 0.002) and matched (10-year survival rate 37.5% vs. 86.3%, p = 0.011) analyses. On multivariable analysis, while resection of the primary NET was not associated with OS (hazard ratio [HR] 0.7, 95% confidence interval [CI] 0.4–1.2, p = 0.195), the presence of extrahepatic metastasis was independently associated with long-term risk of death (HR 3.9, 95% CI 1.7–9.2, p = 0.002).

Conclusions

While surgery should be considered for patients with NF-NELM who have an unresectable primary tumor, operative resection of NF-NELM may not be as beneficial in patients with extrahepatic disease.

Notes

Acknowledgment

Jun-Xi Xiang and Xu-Feng Zhang were supported by the Clinical Research Award of the First Affiliated Hospital of Xi’an Jiaotong University of China (No. XJTU1AF-CRF-2017-004).

Author Contributions

Study design: J.X. Xiang, X.F. Zhang, T.M. Pawlik. Data collection and interpretation: E.W. Beal, L. Aldrighetti, G.A. Poultsides, T.W. Bauer, R.C. Fields, S.K. Maithel, H.P. Marques, M. Weiss. Data analysis: J.X. Xiang, X.F. Zhang. Drafting of the manuscript: X.J. Xiang, X.F. Zhang. Revision of the draft version of the manuscript: X.F. Zhang, T.M. Pawlik.

Conflicts of interest

None declared.

Supplementary material

10434_2018_6751_MOESM1_ESM.tif (3 mb)
Overall survival of non-functional neuroendocrine liver metastasis patients who underwent hepatic resection in different eras (TIFF 3050 kb)
10434_2018_6751_MOESM2_ESM.docx (21 kb)
Supplementary material 2 (DOCX 21 kb)

References

  1. 1.
    Gray KD, Moore MD, Panjwani S, et al. Predicting Survival and Response to Treatment in Gastroesophageal Neuroendocrine Tumors: An Analysis of the National Cancer Database. Ann Surg Oncol. 2018;25:1418-24.CrossRefPubMedCentralGoogle Scholar
  2. 2.
    Saxena A, Chua TC, Sarkar A, et al. Progression and survival results after radical hepatic metastasectomy of indolent advanced neuroendocrine neoplasms (NENs) supports an aggressive surgical approach. Surgery. 2011;149:209-20.CrossRefPubMedCentralGoogle Scholar
  3. 3.
    Frilling A, Modlin IM, Kidd M, et al. Recommendations for management of patients with neuroendocrine liver metastases. Lancet Oncol. 2014;15:e8-21.CrossRefPubMedCentralGoogle Scholar
  4. 4.
    Bilimoria KY, Tomlinson JS, Merkow RP, et al. Clinicopathologic features and treatment trends of pancreatic neuroendocrine tumors: analysis of 9,821 patients. J Gastrointest Surg. 2007;11:1460-7; discussion 7-9.CrossRefPubMedCentralGoogle Scholar
  5. 5.
    Ellison TA, Wolfgang CL, Shi C, et al. A single institution’s 26-year experience with nonfunctional pancreatic neuroendocrine tumors: a validation of current staging systems and a new prognostic nomogram. Ann Surg. 2014;259:204-12.CrossRefPubMedCentralGoogle Scholar
  6. 6.
    Franko J, Feng W, Yip L, Genovese E, Moser AJ. Non-functional neuroendocrine carcinoma of the pancreas: incidence, tumor biology, and outcomes in 2,158 patients. J Gastrointest Surg. 2010;14:541-8.CrossRefPubMedCentralGoogle Scholar
  7. 7.
    Kent RB, 3rd, van Heerden JA, Weiland LH. Nonfunctioning islet cell tumors. Ann Surg. 1981;193:185-90.CrossRefPubMedCentralGoogle Scholar
  8. 8.
    Spolverato G, Bagante F, Aldrighetti L, et al. Management and outcomes of patients with recurrent neuroendocrine liver metastasis after curative surgery: an international multi-institutional analysis. J Surg Oncol. 2017;116:298-306.CrossRefPubMedCentralGoogle Scholar
  9. 9.
    Zhang XF, Beal EW, Weiss M, et al. Timing of disease occurrence and hepatic resection on long-term outcome of patients with neuroendocrine liver metastasis. J Surg Oncol. 2018;117:171-81.CrossRefPubMedCentralGoogle Scholar
  10. 10.
    Rindi G, Kloppel G, Alhman H, et al. TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system. Virchows Arch. 2006;449:395-401.CrossRefPubMedCentralGoogle Scholar
  11. 11.
    Jin K, Xu J, Chen J, et al. Surgical management for non-functional pancreatic neuroendocrine neoplasms with synchronous liver metastasis: a consensus from the Chinese Study Group for Neuroendocrine Tumors (CSNET). Int J Oncol. 2016;49:1991-2000.CrossRefPubMedCentralGoogle Scholar
  12. 12.
    Farley HA, Pommier RF. Treatment of Neuroendocrine Liver Metastases. Surg Oncol Clin N Am. 2016;25:217-25.CrossRefPubMedCentralGoogle Scholar
  13. 13.
    Graff-Baker AN, Sauer DA, Pommier SJ, Pommier RF. Expanded criteria for carcinoid liver debulking: Maintaining survival and increasing the number of eligible patients. Surgery. 2014;156:1369-76; discussion 76-7.CrossRefPubMedCentralGoogle Scholar
  14. 14.
    Klimstra DS, Modlin IR, Coppola D, Lloyd RV, Suster S. The pathologic classification of neuroendocrine tumors: a review of nomenclature, grading, and staging systems. Pancreas. 2010;39:707-12.CrossRefPubMedCentralGoogle Scholar
  15. 15.
    Spolverato G, Vitale A, Ejaz A, et al. Net health benefit of hepatic resection versus intraarterial therapies for neuroendocrine liver metastases: a Markov decision model. Surgery. 2015;158:339-48.CrossRefPubMedCentralGoogle Scholar
  16. 16.
    Kulke MH, Shah MH, Benson AB 3rd, et al. Neuroendocrine tumors, version 1.2015. J Natl Compr Canc Netw. 2015;13:78-108.CrossRefPubMedCentralGoogle Scholar
  17. 17.
    Zerbi A, Falconi M, Rindi G, et al. Clinicopathological features of pancreatic endocrine tumors: a prospective multicenter study in Italy of 297 sporadic cases. Am J Gastroenterol. 2010;105:1421-9.CrossRefPubMedCentralGoogle Scholar
  18. 18.
    Hochwald SN, Zee S, Conlon KC, et al. Prognostic factors in pancreatic endocrine neoplasms: an analysis of 136 cases with a proposal for low-grade and intermediate-grade groups. J Clin Oncol. 2002;20:2633-42.CrossRefPubMedCentralGoogle Scholar
  19. 19.
    Kunz PL, Reidy-Lagunes D, Anthony LB, et al. Consensus guidelines for the management and treatment of neuroendocrine tumors. Pancreas. 2013;42:557-77.CrossRefPubMedCentralGoogle Scholar
  20. 20.
    Mayo SC, de Jong MC, Bloomston M, et al. Surgery versus intra-arterial therapy for neuroendocrine liver metastasis: a multicenter international analysis. Ann Surg Oncol. 2011;18:3657-65.CrossRefPubMedCentralGoogle Scholar
  21. 21.
    Andres A, Toso C, Adam R, et al. A survival analysis of the liver-first reversed management of advanced simultaneous colorectal liver metastases: a LiverMetSurvey-based study. Ann Surg. 2012;256:772-8; discussion 8-9.CrossRefPubMedCentralGoogle Scholar
  22. 22.
    Givi B, Pommier SJ, Thompson AK, Diggs BS, Pommier RF. Operative resection of primary carcinoid neoplasms in patients with liver metastases yields significantly better survival. Surgery. 2006;140:891-7; discussion 7-8.CrossRefPubMedCentralGoogle Scholar
  23. 23.
    Mayo SC, de Jong MC, Pulitano C, et al. Surgical management of hepatic neuroendocrine tumor metastasis: results from an international multi-institutional analysis. Ann Surg Oncol. 2010;17:3129-36.CrossRefPubMedCentralGoogle Scholar
  24. 24.
    Ejaz A, Reames BN, Maithel S, et al. The impact of extrahepatic disease among patients undergoing liver-directed therapy for neuroendocrine liver metastasis. J Surg Oncol. 2017;116:841-7.CrossRefPubMedCentralGoogle Scholar
  25. 25.
    Kennedy AS, Dezarn WA, McNeillie P, et al. Radioembolization for unresectable neuroendocrine hepatic metastases using resin 90Y-microspheres: early results in 148 patients. Am J Clin Oncol. 2008;31:271-9.CrossRefPubMedCentralGoogle Scholar
  26. 26.
    Chambers AJ, Pasieka JL, Dixon E, Rorstad O. The palliative benefit of aggressive surgical intervention for both hepatic and mesenteric metastases from neuroendocrine tumors. Surgery. 2008;144:645-51; discussion 51-3.CrossRefPubMedCentralGoogle Scholar
  27. 27.
    Boudreaux JP, Putty B, Frey DJ, et al. Surgical treatment of advanced-stage carcinoid tumors: lessons learned. Ann Surg. 2005;241:839-45; discussion 45-6.CrossRefPubMedCentralGoogle Scholar
  28. 28.
    Mayo SC, de Jong MC, Pawlik TM. Surgical management and emerging therapies to prolong survival in metastatic neuroendocrine cancer. Ann Surg Oncol. 2011;18 Suppl 3:S220-1; author reply S2-3.CrossRefPubMedCentralGoogle Scholar

Copyright information

© Society of Surgical Oncology 2018

Authors and Affiliations

  • Jun-Xi Xiang
    • 1
  • Xu-Feng Zhang
    • 1
  • Eliza W. Beal
    • 2
  • Matthew Weiss
    • 3
  • Luca Aldrighetti
    • 4
  • George A. Poultsides
    • 5
  • Todd W. Bauer
    • 6
  • Ryan C. Fields
    • 7
  • Shishir Kumar Maithel
    • 8
  • Hugo P. Marques
    • 9
  • Timothy M. Pawlik
    • 2
    • 10
  1. 1.Department of Hepatobiliary Surgery and Institute of Advanced Surgical Technology and EngineeringThe First Affiliated Hospital of Xi’an Jiaotong UniversityXi’anChina
  2. 2.Department of SurgeryThe Ohio State University Wexner Medical CenterColumbusUSA
  3. 3.Department of SurgeryJohns Hopkins HospitalBaltimoreUSA
  4. 4.Department of Surgery, Scientific Institute San RaffaeleVita-Salute San Raffaele UniversityMilanItaly
  5. 5.Department of SurgeryStanford UniversityStanfordUSA
  6. 6.Department of SurgeryUniversity of VirginiaCharlottesvilleUSA
  7. 7.Department of SurgeryWashington University, School of MedicineSt LouisUSA
  8. 8.Department of SurgeryEmory UniversityAtlantaUSA
  9. 9.Department of SurgeryCurry Cabral HospitalLisbonPortugal
  10. 10.Department of SurgeryThe Shelly and Urban Meyer Professor of Cancer Research, The Ohio State UniversityColumbusUSA

Personalised recommendations